Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)

Inclusion Criteria: * Age ≥ 12 and ≤ 65 years at Screening. * History of recurrent asthma symptoms (cough, wheezing, shortness of breath, chest tightness). * Previous medical diagnosis of asthma (confirmed by records, prescriptions, or participant report). * Documented reversible airway obstruction by spirometry: FEV₁ increase ≥ 200 mL and ≥ 12% post-bronchodilator (at screening or prior report). * Moderate asthma (GINA step 3) for ≥ 6 months, clinically stable and controlled with LABA + low-dose inhaled corticosteroid for ≥ 90 days. * ACQ-7 score ≤ 0.75 at Screening. * At Randomization: ACQ-7 score ≤ 0.75 and ≥ 70% adherence during run-in. Exclusion Criteria: * Moderate/severe asthma exacerbation within 90 days prior to screening. * Other pulmonary disease (including predominant COPD). * Symptomatic acute or chronic respiratory infection. * BMI ≥ 40 kg/m². * Use of LAMA within 6 months prior to screening. * Oral or depot corticosteroids within 30 days prior to screening. * Biologic therapy for asthma, allergic rhinitis, or urticaria within 12 months prior to screening. * Systemic vasoconstrictors within 7 days prior to screening. * Known hypersensitivity to formoterol, fluticasone, budesonide, or any component of study drugs. * Active pulmonary tuberculosis or fungal airway infection. * History or presence of ischemic heart disease, severe arrhythmias, cardiac decompensation, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm, pheochromocytoma, hypertro…